Evolving Paradigms in Advanced HCC Systemic Therapies

Hepatocellular carcinoma represents the sixth most common cancer and the third leading cause of cancer-related death worldwide. For over a decade, single-agent sorafenib served as the only standard frontline option for unresectable disease. However, the introduction of immune checkpoint inhibitors, anti-angiogenic antibodies, and tyrosine kinase inhibitors has transformed the treatment landscape. Navigating these options is complex because few randomized trials directly compare novel combination regimens. Consequently, clinicians require high-quality comparative evidence to optimize advanced HCC systemic therapies in daily clinical practice.

Modern combination strategies consistently outperform traditional monotherapies in clinical trials. Specifically, dual immune checkpoint inhibition and immunotherapy combined with anti-VEGF agents have significantly improved patient survival. Furthermore, clinicians must balance efficacy advantages against treatment-related toxicities and underlying hepatic reserve. Therefore, systematic network evaluations provide critical clarity for selecting effective, tailored frontline regimens.

Network Meta-Analysis Design and Methodology

To evaluate first-line treatment strategies, researchers conducted an extensive network meta-analysis of phase III randomized trials. They searched PubMed, EMBASE, Scopus, and the Cochrane Library from inception through May 2025. Overall, the investigators identified seventeen randomized controlled trials involving 12,727 patients with advanced hepatocellular carcinoma. In addition, the study evaluated overall survival, progression-free survival, objective response rates, and grade 3 or higher treatment-related adverse events.

Methodologists applied a random-effects network model using sorafenib and lenvatinib as active reference comparators. Furthermore, the team performed prespecified subgroup analyses to explore how disease characteristics modified therapeutic efficacy. Investigators calculated P-scores to rank the relative performance of each systemic regimen across key clinical outcomes. This analytical method enables robust comparisons across regimens that have not undergone direct head-to-head testing in clinical trials.

Comparative Overall and Progression-Free Survival Outcomes

The network meta-analysis demonstrated substantial overall survival improvements with frontline combination regimens. Specifically, five therapies significantly outperformed sorafenib: nivolumab plus ipilimumab, atezolizumab plus bevacizumab, durvalumab plus tremelimumab, sintilimab plus bevacizumab biosimilar, and camrelizumab plus rivoceranib. Among these combinations, sintilimab plus bevacizumab biosimilar and nivolumab plus ipilimumab demonstrated the greatest survival extensions.

However, comparative advantages differed when evaluating regimens against lenvatinib. Specifically, only sintilimab plus bevacizumab biosimilar and nivolumab plus ipilimumab achieved statistically superior overall survival compared to lenvatinib. Moreover, nivolumab plus ipilimumab secured the highest P-scores for overall survival, progression-free survival, and objective response rates among regulatory-approved dual regimens. Consequently, dual checkpoint inhibition targeting PD-1 and CTLA-4 represents a highly effective first-line option.

Evaluating Safety Profiles and Treatment-Related Adverse Events

Clinicians must carefully evaluate toxicity profiles alongside survival gains when choosing frontline therapies. Notably, the network meta-analysis found that nivolumab plus ipilimumab exhibited severe adverse event rates comparable to sorafenib. This finding highlights the clinical viability and manageable safety profile of dual immune checkpoint blockade in eligible patients.

In contrast, regimens containing anti-VEGF agents or multi-targeted tyrosine kinase inhibitors carry specific risks of hypertension, proteinuria, and bleeding. Therefore, clinicians must perform upper endoscopy to screen for and manage esophageal varices before starting anti-VEGF combinations. Meanwhile, dual immunotherapy regimens require vigilant monitoring for immune-mediated toxicities affecting the liver, bowel, or endocrine organs. Thus, selecting an appropriate regimen requires thorough assessment of baseline hepatic function and comorbidity profiles.

Biomarker and Etiology-Driven Subgroup Stratification

The study demonstrated that therapeutic responses vary markedly according to underlying tumor etiology and baseline biomarkers. Specifically, atezolizumab plus cabozantinib achieved the highest P-score ranking for patients with hepatitis B virus infection. Conversely, atezolizumab plus bevacizumab ranked highest in efficacy for patients with hepatitis C virus-related disease.

Furthermore, durvalumab plus tremelimumab achieved the top ranking for overall survival in patients with non-viral hepatocellular carcinoma. This finding underscores the distinct immune microenvironment of non-viral liver tumors. Additionally, pembrolizumab plus lenvatinib showed the highest P-score ranking for patients with baseline alpha-fetoprotein levels of 400 ng/mL or higher. Therefore, integrating viral status and biomarker levels enables clinicians to select personalized first-line therapies.

Optimizing Clinical Practice and Personalized Regimen Selection

These findings provide clear guidance for multidisciplinary teams managing advanced hepatocellular carcinoma. Rather than adopting a uniform approach, clinicians should personalize frontline therapy based on patient-specific risk factors. In addition, baseline liver reserve remains crucial for determining treatment safety and feasibility.

For patients with significant portal hypertension or elevated bleeding risk, dual immunotherapy combinations offer a safer alternative to anti-VEGF regimens. Meanwhile, anti-VEGF and checkpoint inhibitor combinations remain highly potent options for patients with viral hepatitis and low bleeding risk. Furthermore, multidisciplinary collaboration ensures timely management of toxicities and optimal sequencing of subsequent treatment lines. Consequently, tailored regimen selection maximizes therapeutic efficacy while preserving quality of life.

Which advanced HCC systemic therapies show superior overall survival compared to standard tyrosine kinase inhibitors?

The network meta-analysis identified five combination regimens with superior overall survival compared to sorafenib: nivolumab plus ipilimumab, atezolizumab plus bevacizumab, durvalumab plus tremelimumab, sintilimab plus bevacizumab biosimilar, and camrelizumab plus rivoceranib. However, when compared against lenvatinib, only sintilimab plus bevacizumab biosimilar and nivolumab plus ipilimumab demonstrated statistically significant overall survival advantages. Among regulatory-approved regimens, nivolumab plus ipilimumab achieved the highest overall survival ranking.

How do patient etiology and alpha-fetoprotein levels influence first-line regimen selection in advanced HCC?

Underlying etiology and tumor biomarkers strongly affect treatment responses in advanced hepatocellular carcinoma. In the network meta-analysis, atezolizumab plus cabozantinib ranked highest for hepatitis B infection, while atezolizumab plus bevacizumab showed greatest efficacy in hepatitis C. Conversely, durvalumab plus tremelimumab achieved the top ranking in non-viral hepatocellular carcinoma. Additionally, pembrolizumab plus lenvatinib ranked highest for patients with elevated baseline alpha-fetoprotein levels exceeding 400 ng/mL.

What safety considerations guide the choice between dual immunotherapy and anti-VEGF combinations?

Safety considerations depend on individual patient risk factors and baseline comorbidities. Anti-VEGF combinations carry significant risks of gastrointestinal bleeding, hypertension, proteinuria, and arterial thromboembolism, requiring prior endoscopic evaluation for esophageal varices. In contrast, dual immunotherapy regimens avoid vascular and bleeding toxicities but carry risks of immune-related adverse events affecting hepatic, gastrointestinal, and endocrine systems. Clinicians must evaluate baseline portal hypertension and autoimmune status during regimen selection.

Disclaimer: This content is for informational and educational purposes only. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

1. Chua WY et al. Integrating efficacy and safety profile in advanced HCC: A network meta-analysis of first-line systemic therapies. JNCI Cancer Spectr. 2026 Aug 21. doi: undefined. PMID: 42627365.


2. Vogel A, Chan SL, Dawson LA, et al. Hepatocellular carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2025;36(5):491-506.


3. Sonbol MB, Riaz IB, Naqvi SAA, et al. Systemic therapy and sequencing options in advanced hepatocellular carcinoma: A systematic review and network meta-analysis. JAMA Oncol. 2020;6(12):e204930.